Advances in Cancer Immunotherapy™ Regional Education Programs

Get in-depth education focused on your specialty

Join the Society for Immunotherapy of Cancer (SITC) for its newly redesigned Advances in Cancer Immunotherapy™ (ACI) educational series, with each program offering focused clinical education on a disease state or topic. Attendees of these half-day innovative programs will have the opportunity for in-depth training in immunotherapy treatment for a variety of topics from leaders in this specific field. The ACI program will also feature a discussion of closed cases submitted from attendees to hear guidance and insights from expert faculty. This meeting is certified for CME, CNE, CPE, and MOC credits.

ACIs are free for healthcare professionals in the clinical setting, students and patient advocates.

The ACI programs will take place as planned for the dates/formats listed below, but are subject to change.

Date	ACI Program Location	Registration Link
Wednesday, October 27, 2021	ACI: A Focus on Genitourinary Cancers (VIRTUAL ONLY)	Register Now!
Wednesday, November 3, 2021	ACI: A Focus on MSI-High and TMB-High Cancers (VIRTUAL ONLY)	Register Now!
Wednesday, November 17, 2021	ACI: A Focus on Gastrointestinal Cancers (VIRTUAL ONLY)	Register Now!
Wednesday, February 2, 2022	ACI: A Focus on Hematologic Malignancies (HYBRID)	Register Now!
Thursday, March 24, 2022	ACI: A Focus on Biomarkers (HYBRID)	Register Now!
Thursday, April 28, 2022	ACI: A Focus on Toxicity Management (HYBRID)	Register Now!

The programs also provide online, CME-, CPE-, CNE- and MOC-certified companion activities, which are accessible independently by those unable to attend live meetings or serve as helpful references for attendees as they incorporate what they learned into practice.

Series Learning Objectives

Upon completion of this activity, participants should be able to:

• Identify the common approaches to cancer immunotherapy and their related mechanisms.
• Summarize recent updates in cancer immunotherapy and toxicity management for key disease states.
• Implement cancer immunotherapy for key disease states into clinical practice appropriately.

Full accreditation information may be found by clicking on each activity's link above.

 

  

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 09/17/2021)